Immune checkpoint inhibitor-associated acute kidney injury
Common electrolyte disorders associated with immune checkpoint inhibitors
Gupta S, et al. Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer 2021; 9:e003467. doi: 10.1136/jitc-2021-003467
Gupta S, et al. Immune checkpoint inhibitor nephrotoxicity: Update 2020. Kidney360 2020; 1:130–140. https://kidney360.asnjournals.org/content/1/2/130
Brahmer JR, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 2021; 9:e002435. doi: 10.1136/jitc-2021-002435
Kitchlu A, et al. A systematic review of immune checkpoint inhibitor-associated glomerular disease. Kidney Int Rep 2021; 6:66–77. doi: 10.1016/j.ekir.2020.10.002
Uppal NN, et al. Electrolyte and acid-base disorders associated with cancer immunotherapy. Clin J Am Soc Nephrol [Published online ahead of print January 21, 2022]. doi: 10.2215/CJN.14671121; https://cjasn.asnjournals.org/content/early/2022/02/06/CJN.14671121
Wanchoo R, et al. Immune checkpoint inhibitor-associated electrolyte disorders: Query of the Food and Drug Administration Adverse Event Reporting System. Kidney Int 2021; 100:945–947. doi: 10.1016/j.kint.2021.06.001
Seethapathy H, et al. Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors. Nephrol Dial Transplant 2021; 36:2241–2247. doi: 10.1093/ndt/gfaa272
Manohar S, et al. Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: Meta-analysis. Nephrol Dial Transplant 2019; 34:108–117. doi: 10.1093/ndt/gfy105
Vogel WV., et al. Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol 2012; 30:e7–e10. doi: 10.1200/JCO.2011.37.9693
Mills TA, et al. Parathyroid hormone-related peptide-linked hypercalcemia in a melanoma patient treated with ipilimumab: Hormone source and clinical and metabolic correlates. Semin Oncol 2015; 42:909–914. doi: 10.1053/j.seminoncol.2015.09.006
Chalan P, et al. Thyroid dysfunctions secondary to cancer immunotherapy. J Endocrinol Invest 2018; 41:625–638. doi: 10.1007/s40618-017-0778-8
Ferris RL, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016; 375:1856–1867. doi: 10.1056/nejmoa1602252